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Abstract
Introduction: Denosumab decreases the incidence of skeletal-related events in patients with metastatic
bone disease and is used routinely as part of the therapeutic strategy for various cancers. However, it is
associated with a high risk of hypocalcemia with incidence of high-grade hypocalcemia (defined as total
calcium < 7mg/dl) as high as 5.1% in patients with castrate-resistant prostate cancer. We present a case of
severe hypocalcemia presenting with status epilepticus 32 days after administration of denosumab. Case: A
83 year old African American man presented to the emergency room with status epilepticus. Initial labs
revealed a critically low calcium (Ca) of <5mg/dl (8.5-10.1) with albumin 2.2 g/dl (3.4-5.0), ionized
calcium 1.09 mg/dl (4.6-5.1) and creatinine (Cr) 3.68 mg/dl (0.67-1.17). QTC was prolonged at 544ms
(<400ms). He was intubated for airway protection and a continuous infusion of intravenous calcium
gluconate was initiated. Three months prior, he had been diagnosed with prostate cancer with diffuse
osteoblastic metastases to his ribs, cervical, thoracic, lumbar and sacral vertebrae, right humerus and
bilateral iliac bones. He received a first dose of conventional chemotherapy and 120mg denosumab
subcutaneously 32 days prior to hospital admission. Lab investigations then were pertinent for Ca of 9
mg/dl, Cr 1.46 mg/dl, and alkaline phosphatase 362 Units/L (25-125). A 25-hydroxy vitamin D (25-D) was
not checked. Further evaluation demonstrated intact parathyroid hormone 677.2 pg/ml (18.4-80.1), alkaline
phosphatase 397 Units/L, phosphorus 3.6 mg/dl (2.5-4.9) and 25-D 18 ng/ml (30-100). He was also found to
have metastatic obstruction of both ureters which had resulted in acute kidney injury. He was slowly
weaned off the intravenous calcium and started on calcitriol 2mcg twice daily, 4 gram elemental calcium
daily via feeding tube and cholecalciferol 6000 units daily. Calcium levels remained stable at 8.0-8.5mg/dl
on this regimen. Given the extensive metastatic disease, the patient’s family elected to pursue hospice care,
and he passed away 9 days later. Conclusion: Patients with osteoblastic metastases and renal impairment
are at particularly increased risk of hypocalcemia after denosumab, which can be potentially life-
threatening. Physicians caring for patients with metastatic prostate cancer should ensure that vitamin D
levels are replete and calcium levels are normal prior to administration of denosumab, monitor calcium
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levels closely, and counsel them about the signs and symptoms of hypocalcemia to allow prompt diagnosis
and treatment.
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